Keywords: USA, Overactive bladder drug market, Frost & Sullivan, Mirabegron

US overactive bladder drug market poised for robust growth with new products and expanding patient population

Article | 14 May 2010

Print This

The USA’s overactive bladder (OAB) treatment market is slated to witness strong growth, fuelled by the increase in diagnosed ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in